FINWIRES · TerminalLIVE
FINWIRES

Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight

By

AgomAb Therapeutics (AGMB) has an average rating of buy and mean price target of $33.29, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles